Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Monovalent Oral Polio Vaccine Type 2 in Children and Infants
NCT02521974Phase 4Completed
- Sponsor
- Fighting Infectious Diseases in Emerging Countries
- Start
- Oct 2015
- Primary completion
- Jul 2016
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 4, open-label, single-arm trial of Sabin OPV2 in poliomyelitis, sponsored by Fighting Infectious Diseases in Emerging Countries. Primary endpoints: Number of Subjects Experiencing SAEs, Severe AEs (Grade 3), and/or IMEs at 6 months and Seroprotection Rate of Type 2 Polio Neutralizing Antibodies at 28 days. Started Oct 2015; status: completed.
02
Drugs
Sabin OPV2
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT02521974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02521974.